The responsiveness of estrogen receptor (ER)-positive breast cancer to endocrine therapy is frequently reduced in cells over-expressing c-erbB-2. Stimulation of ER suppresses c-erbB-2, indicating that estrogen controls the activity of c-erbB-2. Heregulin (HRG) has been described to bind to c-erbB-3/
SUCI02 inhibits the erbB-2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells
β Scribed by Xiao-Feng Zhu; Jing-Song Wang; Li-Ling Cai; Yi-Xin Zeng; Dajun Yang
- Book ID
- 108583586
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 219 KB
- Volume
- 97
- Category
- Article
- ISSN
- 1347-9032
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract The epidermal growth factor (EGF) plays a role in the development of prostate cancer, which becomes essential after androgen resistance has emerged. The EGF receptor (EGFR) is therefore a potential target for anticancer therapy. We evaluated the effects of ZD1839 (βIressaβ), an orally a
## Abstract Overexpression of the interleukinβ2 receptor (ILβ2R) Ξ± chain in tumor cells is associated with tumor progression and a poor patient prognosis. ILβ2RΞ± is responsible for the high affinity binding of the receptor to ILβ2, leading to activation of several proliferative and antiβapoptotic i